Clinical Trial Update: Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating gemcitabine plus pazopanib for chemotherapy-naïve, advanced/metastatic urothelial carcinoma ineligible for cisplatin was terminated; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Pazopanib (Votrient) (Pazopanib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-08-22